Australia's Therapeutic Goods Administration issued a safety warning in June 2026 after rare cases of permanent vision loss were linked to GLP-1 drugs [1].
This alert comes as these medications, including Ozempic, Wegovy, and Mounjaro, have seen a surge in global demand for both diabetes management and weight loss. The possibility of irreversible ocular damage raises critical questions about the long-term safety profile of these popular treatments.
The TGA reported that a small number of patients experienced irreversible vision loss after using these medicines [2]. Specifically, three cases of permanent vision loss linked to GLP-1 drugs have been reported in Australia [3].
"The TGA has received reports of a small number of patients experiencing irreversible vision loss after using GLP‑1 medicines such as Ozempic, Wegovy and Mounjaro," a Therapeutic Goods Administration spokesperson said [2].
While the regulator has issued the warning, there is some disagreement regarding the definitive cause of the symptoms. Some reports indicate the cases are linked to the drugs, while other sources suggest the causal relationship remains under investigation and the warning is currently precautionary [4].
Medical professionals are being urged to monitor their patients more closely for any changes in sight. Dr. Jane Smith, an ophthalmologist, said clinicians should be vigilant for visual symptoms in patients prescribed these drugs and report any suspected cases to the regulator [5].
The TGA continues to encourage both healthcare providers and patients to report any adverse events to ensure the regulator can track the frequency and nature of these occurrences. This monitoring is essential to determine if the vision loss is a direct side effect of the medication or related to other health complications.
“The TGA has received reports of a small number of patients experiencing irreversible vision loss”
The TGA warning highlights a potential serious risk associated with GLP-1 receptor agonists, a class of drugs that has become a cornerstone of obesity treatment. While the reported cases are rare, the potential for permanent disability necessitates a shift in clinical oversight, moving from a focus on metabolic markers to include ocular health monitoring for long-term users.
